Table 2 The 2- and 5-year cumulative AML incidences with mortality as the competing risk and with left truncation, and the 2- and 5-year OS probabilities with left truncation
Cumulative AML incidences, % (95% CI) | Lenalidomide-treated | Untreated |
|---|---|---|
Overall population | (n =295) | (n =125) |
Two-year | 6.9 (3.3–13.9) | 12.1 (7.0–20.3) |
Five-year | 22.8 (17.1–30.3) | 19.9 (12.9–30.0) |
Patients with WHO-defined isolated del(5q) a | (n =160) | (n =85) |
Two-year | 6.6 (2.5–16.7) | 7.4 (3.1–16.9) |
Five-year | 18.1 (11.3–28.1) | 16.9 (9.4–29.4) |
OS probabilities, % (95% CI) | Lenalidomide-treated | Untreated |
Overall population | (n =295) | (n =125) |
Two-year | 89.9 (84.1–96.0) | 74.4 (66.1–83.7) |
Five-year | 53.7 (46.6–61.9) | 40.5 (30.9–53.1) |
Patients with WHO-defined isolated del(5q) a | (n =160) | (n =85) |
Two-year | 93.5 (87.5–99.9) | 76.1 (66.4–87.1) |
Five-year | 60.2 (51.1–71.0) | 44.4 (32.8–60.3) |
